Aventis and Diversa Extend Collaboration.Business Editors and Health/Medical Writers BIOWIRE2K SAN DIEGO--(BW HealthWire)--April 13, 2000 Diversa Corp. (Nasdaq:DVSA DVSA Dundas Valley School of Art (California) DVSA Baker Digital Voice Stress Analysis (Baker Group) DVSA Delaware Valley Sprint Association (Philadelphia, PA former club) ) and Aventis Animal Nutrition S.A., a subsidiary of Aventis S.A., Thursday announced that, based on progress made in the program to date, they have extended their research agreement beyond the initial six month period to develop a biocatalytic bi·o·cat·a·lyst n. A substance, especially an enzyme, that initiates or modifies the rate of a chemical reaction in a living body; a biochemical catalyst. bi process used to manufacture a key Aventis product for animal nutrition. Aventis has developed a unique manufacturing process, and Diversa is using a combination of its proprietary evolution and screening technologies to optimize optimize - optimisation the biocatalyst bi·o·cat·a·lyst n. A substance, especially an enzyme, that initiates or modifies the rate of a chemical reaction in a living body; a biochemical catalyst. bi . The extension resulted in additional research funding Research funding is a term generally covering any funding for scientific research, in the areas of both "hard" science and technology and social science. The term often connotes funding obtained through a competitive process, in which potential research projects are evaluated and to Diversa, although specific financial terms were not disclosed. Diversa Corp. is a global leader in developing and applying proprietary technologies to discover and optimize novel genes and gene pathways from diverse environmental sources. The company's fully integrated approach extends from discovery and gene evolution to production of novel enzymes. Diversa's powerful, proprietary evolution technologies facilitate the optimization optimization Field of applied mathematics whose principles and methods are used to solve quantitative problems in disciplines including physics, biology, engineering, and economics. of the best genes found in nature, which can be used to generate ideal product solutions across varied markets including agricultural, chemical processing, industrial and pharmaceutical. Within these markets, the company is pursuing multi-billion dollar market segments where its technologies and products will create high value and competitive advantages for its strategic partners and customers. Diversa's strategic partners are market leaders across multiple industries and include Novartis Seeds AG, Novartis Agribusiness agribusiness Agriculture operated by business; specifically, that part of a modern national economy devoted to the production, processing, and distribution of food and fibre products and byproducts. Biotechnology Research Inc., The Dow Chemical Co., Aventis Animal Nutrition S.A. and Finnfeeds International Limited. Aventis S.A. is a world leader in life sciences. Focused on two core business areas -- pharmaceuticals and agriculture -- Aventis is dedicated to improving life through the discovery and development of innovative products in the fields of prescription drugs prescription drug Prescription medication Pharmacology An FDA-approved drug which must, by federal law or regulation, be dispensed only pursuant to a prescription–eg, finished dose form and active ingredients subject to the provisos of the Federal Food, Drug, , vaccines, therapeutic proteins, crop production and protection, animal health and nutrition. With global corporate headquarters in Strasbourg, France, Aventis employs around 90,000 people in 150 countries and recorded sales in 1999 of more than euro 18 billion. Statements in this press release that are not strictly historical are "forward-looking" statements which involve a high degree of risk and uncertainty. Such statements are only predictions and the actual events or results may differ materially from those projected in such forward-looking statements forward-looking statement A projected financial statement based on management expectations. A forward-looking statement involves risks with regard to the accuracy of assumptions underlying the projections. . Factors that could cause or contribute to differences include, but are not limited to, risks involved with the company's new and uncertain technologies, risks associated with the company's dependence on patents and proprietary rights, risks associated with the company's protection and enforcement of its patents and proprietary rights and the company's dependence on existing strategic alliances and the development or availability of competitive products or technologies. These factors and others are more fully described in the company's Registration Statement on Form S-1, as filed with the Securities and Exchange Commission. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion